Table 1– Baseline characteristics at initial assessment
ParameterAcute exacerbationNon-acute exacerbationOverall
Subjects272855
Age yrs61.92±5.2758.15±8.9460.04±7.51
Males202141
Body mass index26.87±2.9626.02±4.2926.44±3.76
FVC % pred59.32±14.0260.17±21.6259.76±18.20
FEV1 % pred63.46±14.4860.58±18.8061.96±16.77
DL,CO % pred30.73±10.1829.13±12.8729.91±11.51
TLC % pred62.81±11.5965.45±13.5264.13±12.53
Cytotoxic antibodies141226
LVEF %59.37±7.4259.71±5.0459.53±6.35
RVSP
 ECHO mmHg28.69±13.1428.08±8.9128.39±10.88
 RHC mmHg32.45±6.6230.40±6.9731.43±6.78
mPpa mmHg22.47±8.1719.78±4.8721.13±6.80
Ppcw mmHg7.47±4.218.00±3.357.73±3.87
CO L·min−15.29±1.395.54±1.475.40±1.41
  • Data are presented as n or mean±sd. FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; DL,CO: diffusing capacity of the lung for carbon monoxide; TLC: total lung capacity; LVEF: left ventricular ejection fraction; RVSP: right ventricular systolic pressure; RHC: right heart catheterisation; mPpa: mean pulmonary arterial pressure; Ppcw: pulmonary capillary wedge pressure; CO: cardiac output.